What is ICI Myocarditis?
ICI myocarditis is a rare but potentially fatal immune-mediated inflammatory cardiac toxicity that occurs when immune checkpoint inhibitor cancer therapy triggers autoreactive T cells to attack cardiac muscle, resulting in myocardial inflammation, conduction abnormalities, arrhythmias, and heart failure. 1
Pathophysiology
ICI myocarditis develops when checkpoint blockade (PD-1/PD-L1 or CTLA-4 inhibitors) removes normal immune tolerance mechanisms, leading to:
- Activation of autoreactive CD8+ T cells that recognize shared antigens between tumor cells and cardiac myocytes (particularly α-myosin) 2, 3
- Loss of regulatory T cell function and expansion of cytotoxic lymphocytes that infiltrate the myocardium 4, 5
- Macrophage polarization toward pro-inflammatory M1 phenotypes with amplification through inflammatory cascades involving STAT1/NF-κB pathways 3
- Multicellular crosstalk among T cells, macrophages, fibroblasts, endothelial cells, and neutrophils that perpetuates myocardial damage 3
Epidemiology and Risk Factors
- Incidence: 0.04-1.7% of patients receiving ICIs, though likely underdiagnosed 5, 6
- Timing: Median onset 34 days after ICI initiation, but can occur after just 1-2 doses or even after 460+ days 6, 7
- Higher risk with:
Clinical Manifestations
Symptoms are often nonspecific and easily missed, including:
- Myalgia, chest pain, shortness of breath (can mimic pneumonitis) 8
- Fatigue, weakness
- Palpitations, syncope
- Fulminant presentations: cardiogenic shock, cardiac arrest, complete heart block 6
Key diagnostic findings:
- Elevated troponin (troponin ≥1.5 ng/mL associated with 4-fold increased risk of major adverse cardiac events) 6
- ECG abnormalities: conduction disease, QTc prolongation, ST-T wave changes, heart block 9
- Elevated BNP/NT-pro-BNP (>500 pg/mL suggests grade 3 toxicity) 9
- Arrhythmias: atrial fibrillation, ventricular tachycardia 1
- Left ventricular systolic dysfunction on echocardiogram 1
Diagnostic Workup
When ICI myocarditis is suspected, prompt comprehensive evaluation is critical 1:
- ECG
- Troponin, BNP or NT-pro-BNP
- C-reactive protein
- Viral titers (to exclude viral myocarditis)
- Echocardiogram with global longitudinal strain
- Cardiac MRI (most sensitive imaging modality using Lake Louise Criteria) 4
- Endomyocardial biopsy if diagnosis highly suspected with otherwise negative workup 1
Prognosis
ICI myocarditis carries the highest mortality of all immune-related adverse events 5, 10:
- Mortality rate approximately 23-50% despite treatment 8
- Major adverse cardiac events (cardiovascular death, cardiogenic shock, cardiac arrest, hemodynamically significant heart block) occur in ~50% of diagnosed cases 6
- Conduction abnormalities are the primary mode of death, often with preserved ejection fraction 8
Common Pitfalls
- Delayed recognition due to nonspecific symptoms that overlap with other conditions
- Failure to maintain suspicion beyond the early treatment period—myocarditis can present very late 7
- Misattribution of symptoms to pneumonitis or other immune-related adverse events
- Underestimating severity when troponin is only mildly elevated—even modest elevations warrant aggressive evaluation
- Rebound troponin elevation during steroid taper may represent myocardial remodeling rather than active injury in clinically stable patients 11